This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rocca, A. S. Articles by Brubaker, P. L. Search for Related Content PubMed PubMed Citation Articles by Rocca, A. S. Articles by Brubaker, P. L. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Dietary Fats Hazardous Substances DB GLUCAGON OLEIC ACID PALMITIC ACID SODIUM PALMITATE

Monounsaturated Fatty Acid Diets Improve Glycemic Tolerance through Increased Secretion of Glucagon-Like Peptide-1¹

Departments of Physiology (A.S.R., J.L.G., J.K., P.L.B.) and Medicine (P.L.B.), University of Toronto, Toronto, Ontario, Canada

Address all correspondence and requests for reprints to: Patricia L. Brubaker, Ph.D., Rm 3366, Medical Sciences Building, 1 King’s College Circle, University of Toronto, Toronto, Ontario, Canada, M5S 1A8. E-mail: p.brubaker{at}utoronto.ca

Diets enriched in monounsaturated fatty acids (MUFA)s have been shown to benefit glycemic control. Furthermore, MUFAs specifically stimulate secretion of the antidiabetic hormone, Glucagon-like peptide-1 (GLP-1) in vitro. To determine whether the MUFA-induced benefit in glycemic tolerance in vivo is due to increased GLP-1 release, lean Zucker rats were pair-fed a synthetic diet containing 5% fat derived from either olive oil (OO; 74% MUFA) or coconut oil (CO; 87% saturated fatty acids; SFA) for 2 weeks. Food intake and body weight gain were similar for both groups over the feeding period. The OO group had improved glycemic tolerance compared with the CO group in both oral and duodenal glucose tolerance tests [area under curve (AUC) 121 ± 61 vs. 290 ± 24 mM·120 min, P < 0.05; and 112 ± 28 vs. 266 ± 65 mM·120 min, P < 0.05, respectively]. This was accompanied by increased secretion of gut glucagon-like immunoreactivity (gGLI; an index of GLP-1 levels) in the OO rats compared with the CO rats (402 ± 96 vs. 229 ± 33 pg/ml at t = 10 min, P < 0.05). Tissue levels of GLP-1 and plasma insulin and glucagon levels were not different between the two groups. To determine the total contribution of GLP-1 to the enhanced glycemic tolerance in OO rats, the GLP-1 receptor antagonist exendin^9–39 (Ex^9–39) was infused 3 min before a duodenal glucose tolerance test. Ex^9–39 abolished the benefit in glycemic tolerance conferred by OO feeding (OO+Ex^9–39 vs. CO+Ex^9–39, P = NS), and resulted in a deterioration of glycemic tolerance in the OO+Ex^9–39 group when compared with the OO controls (AUC 331 ± 21 vs. 112 ± 28 mM·120 min, P < 0.05). To probe the mechanism by which the OO diet enhanced GLP-1 secretion, a GLP-1-secreting L cell line was incubated for 24 h with either 100 µM oleic acid (MUFA) or 100 µM palmitic acid (SFA) and subsequently challenged with GIP, a known stimulator of the L cell. Preexposure to oleic acid but not to palmitic acid significantly increased GIP-induced GLP-1 secretion when compared with controls (55 ± 12% vs. 34 ± 9%, P < 0.01). These results demonstrate that the benefit in glycemic tolerance obtained with MUFA diets occurs in association with increased GLP-1 secretion, through a mechanism of enhanced L cell sensitivity. These results suggest that diet therapy with MUFAs may be useful for the treatment of patients with impaired glucose tolerance and/or type 2 diabetes through increased GLP-1 secretion.

This article has been cited by other articles:

				M A Martinez-Gonzalez, C d. l. Fuente-Arrillaga, J M Nunez-Cordoba, F J Basterra-Gortari, J J Beunza, Z Vazquez, S Benito, A Tortosa, and M Bes-Rastrollo Adherence to Mediterranean diet and risk of developing diabetes: prospective cohort study BMJ, June 14, 2008; 336(7657): 1348 - 1351. [Abstract] [Full Text] [PDF]

				S. R. Bloom, F. P. Kuhajda, I. Laher, X. Pi-Sunyer, G. V. Ronnett, T. M.M. Tan, and D. S. Weigle The Obesity Epidemic: Pharmacological Challenges Mol. Interv., April 1, 2008; 8(2): 82 - 98. [Abstract] [Full Text] [PDF]

				B. J. Bradford, K. J. Harvatine, and M. S. Allen Dietary Unsaturated Fatty Acids Increase Plasma Glucagon-Like Peptide-1 and Cholecystokinin and May Decrease Premeal Ghrelin in Lactating Dairy Cows J Dairy Sci, April 1, 2008; 91(4): 1443 - 1450. [Abstract] [Full Text] [PDF]

				J. A. Paniagua, A. G. de la Sacristana, E. Sanchez, I. Romero, A. Vidal-Puig, F. J. Berral, A. Escribano, M. J. Moyano, P. Perez-Martinez, J. Lopez-Miranda, et al. A MUFA-Rich Diet Improves Posprandial Glucose, Lipid and GLP-1 Responses in Insulin-Resistant Subjects J. Am. Coll. Nutr., October 1, 2007; 26(5): 434 - 444. [Abstract] [Full Text] [PDF]

				J. S. Perona, O. Vogler, J. M. Sanchez-Dominguez, E. Montero, P. V. Escriba, and V. Ruiz-Gutierrez Consumption of Virgin Olive Oil Influences Membrane Lipid Composition and Regulates Intracellular Signaling in Elderly Adults With Type 2 Diabetes Mellitus J. Gerontol. A Biol. Sci. Med. Sci., March 1, 2007; 62(3): 256 - 263. [Abstract] [Full Text] [PDF]

				R. Iakoubov, A. Izzo, A. Yeung, C. I. Whiteside, and P. L. Brubaker Protein Kinase C{zeta} Is Required for Oleic Acid-Induced Secretion of Glucagon-Like Peptide-1 by Intestinal Endocrine L Cells Endocrinology, March 1, 2007; 148(3): 1089 - 1098. [Abstract] [Full Text] [PDF]

				C. N. Sullivan, S. J. Raboin, S. Gulley, N. T. Sinzobahamvya, G. M. Green, J. R. Reeve Jr., and A. I. Sayegh Endogenous cholecystokinin reduces food intake and increases Fos-like immunoreactivity in the dorsal vagal complex but not in the myenteric plexus by CCK1 receptor in the adult rat Am J Physiol Regulatory Integrative Comp Physiol, March 1, 2007; 292(3): R1071 - R1080. [Abstract] [Full Text] [PDF]

				R. A Reimer Meat hydrolysate and essential amino acid-induced glucagon-like peptide-1 secretion, in the human NCI-H716 enteroendocrine cell line, is regulated by extracellular signal-regulated kinase1/2 and p38 mitogen-activated protein kinases. J. Endocrinol., October 1, 2006; 191(1): 159 - 170. [Abstract] [Full Text] [PDF]

				P. T. Gunnarsson, M. S. Winzell, C. F. Deacon, M. O. Larsen, K. Jelic, R. D. Carr, and B. Ahren Glucose-Induced Incretin Hormone Release and Inactivation Are Differently Modulated by Oral Fat and Protein in Mice Endocrinology, July 1, 2006; 147(7): 3173 - 3180. [Abstract] [Full Text] [PDF]

				C. Thomsen, H. Storm, J. J Holst, and K. Hermansen Differential effects of saturated and monounsaturated fats on postprandial lipemia and glucagon-like peptide 1 responses in patients with type 2 diabetes Am. J. Clinical Nutrition, March 1, 2003; 77(3): 605 - 611. [Abstract] [Full Text] [PDF]

				Y. Anini and P. L. Brubaker Role of Leptin in the Regulation of Glucagon-Like Peptide-1 Secretion Diabetes, February 1, 2003; 52(2): 252 - 259. [Abstract] [Full Text] [PDF]